Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CTSV | O60911 | 4/20 | 0.45 |
| ▸ | CTSL | P07711 | 4/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.43 |
| ▸ | MGMT | P16455 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12253971 | 0.90 | ALDH1A1 (0.46) | PTPN1MAPTKMT2ATDP1L3MBTL1 | |
| SCHEMBL14228268 | 0.87 | MGMT (0.48) | PTPN1MAPTPTGER1PTGER4PTGER3 | |
| Glycine SCHEMBL10470638 | 0.87 | PTPN1 (0.41) | PTPN1MAPTPTGER1PTGER4PTGER3 | |
| SCHEMBL7822540 | 0.84 | CTSV (0.53) | MAPTCTSVCTSLMEN1KMT2A | |
| SCHEMBL10473218 | 0.83 | MEN1 (0.40) | PTPN1MAPTCTSVCTSLPTGER1 | |
| SCHEMBL14199914 | 0.83 | HPGD (0.47) | MAPTMEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL14450789 | 0.83 | HPGD (0.47) | MAPTMEN1KMT2ASMN1; SMN2TDP1 | |
| SCHEMBL14199912 | 0.82 | HPGD (0.46) | MAPTMEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL14199913 | 0.82 | MEN1 (0.53) | MAPTMEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL9348425 | 0.82 | SMN1; SMN2 (0.57) | MAPTCTSVCTSLMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100484955-C | Analog of actinomycin D | UNIV LANZHOU (CN) | 2009-05-06 | — | — | CN | claimed |
| CN-1563080-A | Analog of actinomycin D | UNIV LANZHOU (CN) | 2005-01-12 | — | — | CN | claimed |
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8653261-B2 | Modified actinomycin-based nucleic acid stains and methods of their use | Life Technologies Corporation (US) | 2014-02-18 | — | — | US | disclosed |
| US-20110236887-A1 | MODIFIED ACTINOMYCIN-BASED NUCLEIC ACID STAINS AND METHODS OF THEIR USE | Life Techologies Corporation (US) | 2011-09-29 | — | — | US | disclosed |
| EP-2314599-A1 | Glycopeptide antibiotic monomer derivatives | National University Corporation Nagoya University (JP) | 2011-04-27 | — | — | EP | disclosed |
| CN-101429235-A | New high-efficiency low-toxicity actinomycin type D antineoplastic compound | UNIV LANZHOU (CN) | 2009-05-13 | — | — | CN | disclosed |
| CN-100484955-C | Analog of actinomycin D | UNIV LANZHOU (CN) | 2009-05-06 | — | — | CN | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1818340-A1 | GLYCOPEPTIDE ANTIBIOTIC MONOMER DERIVATIVES | National University Corporation Nagoya University (JP) | 2007-08-15 | — | — | EP | disclosed |
| CN-1563080-A | Analog of actinomycin D | UNIV LANZHOU (CN) | 2005-01-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | PTPN1 806/4885MCL1 4113/4885MAPT 4669/4885 |
| US-20110236887-A1 | MODIFIED ACTINOMYCIN-BASED NUCLEIC ACID STAINS AND METHODS OF THEIR USE | FBL, NSUN2, XRN2 | PTPN1 4644/4885MCL1 913/4885MAPT 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.